<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01410383</url>
  </required_header>
  <id_info>
    <org_study_id>KBT 009</org_study_id>
    <nct_id>NCT01410383</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care</brief_title>
  <acronym>AKKA</acronym>
  <official_title>A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karo Bio AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karo Bio AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eprotirome is a liver selective thyroid hormone that can reduce several independent risk
      factors for cardiovascular disease, while an euthyroid state is preserved in the extrahepatic
      tissue.

      The purpose of this Phase III study is to assess the long-term efficacy and safety of
      Eprotirome in Patients with heterozygous Familial Hypercholesterolaemia who are on optimal
      standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in low-density lipoprotein cholesterol (LDL-C) from baseline</measure>
    <time_frame>12 weeks treatment</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Heterozygous Familial Hypercholesterolaemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eprotirome I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eprotirome II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets taken daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eprotirome</intervention_name>
    <description>Tablets taken daily</description>
    <arm_group_label>Eprotirome I</arm_group_label>
    <other_name>KB2115</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eprotirome</intervention_name>
    <description>Tablets taken daily</description>
    <arm_group_label>Eprotirome II</arm_group_label>
    <other_name>KB2115</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed HeFH and 18 years of age at screening

          -  Presence of clinical atherosclerotic disease that confers high risk for CAD events
             together with an LDL-C more than 2 mmol/L (more than 80 mg/dL)

          -  Presence of risk factors for CVD (other than the HeFH diagnosis) together with an
             LDL-C more than 2.5 mmol/L (more than 100 mg/dL)

          -  On an optimal standard of care, defined as being on a stable dose of statin
             (rosuvastatin, atorvastatin, or simvastatin) with or without ezetimibe for 8 weeks
             prior to randomisation

        Exclusion Criteria:

          -  Significant health problems in recent past including heart failure,cardiac
             electrophysiologic instability, rheumatoid arthritis, thyroid dysfunction, liver
             disease, cancer, secondary dyslipidaemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kastelein, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Center (AMC) of the University of Amsterdam</affiliation>
  </overall_official>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>August 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2011</study_first_posted>
  <last_update_submitted>August 31, 2012</last_update_submitted>
  <last_update_submitted_qc>August 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercholesterolemia,</keyword>
  <keyword>dyslipidemia,</keyword>
  <keyword>thyroid,</keyword>
  <keyword>safety,</keyword>
  <keyword>Heterozygous Familial Hypercholesterolaemia</keyword>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

